An Open-Label Trial of Divalproex in Children and Adolescents with Bipolar Disorder

Karen Dineen Wagner, Elizabeth B. Weller, Gabrielle A. Carlson, Gary Sachs, Joseph Biederman, Jean A. Frazier, Patricia Wozniak, Katherine Tracy, Ronald A. Weller, Charles Bowden

Research output: Contribution to journalArticle

129 Citations (Scopus)

Abstract

Objective: This study evaluated the safety and effectiveness of divalproex sodium (Depakote®) in the treatment of youths with bipolar disorder. Method: Forty bipolar disorder patients aged 7 to 19 years, with a manic, hypomanic, or mixed episode, enrolled in an open-label study of divalproex (2-8 weeks), followed by a double-blind, placebo-controlled period (8 weeks). Results: Twenty-two subjects (61%) showed ≥50% improvement in Mania Rating Scale (MRS) scores during the open-label period. Significant (p < .001) improvements from baseline were seen for mean scores of all efficacy measures, including the MRS, Manic Syndrome Scale, Behavior and Ideation Scale, Brief Psychiatric Rating Scale, Clinical Global Impressions Severity scale, and Hamilton Rating Scale for Depression. Of the 23 subjects who discontinued the study during the open-label period, 6 (15%) discontinued for ineffectiveness, 6 (15%) for intolerance, 6 (15%) for noncompliance, and 6 (15%) for other reasons. Adverse events were generally mild or moderate in severity, with the most common being headache, nausea, vomiting, diarrhea, and somnolence. Laboratory data results were unremarkable. Too few subjects participated in the double-blind period for statistical analysis. Conclusion: This study provides preliminary support for the safety and effectiveness of divalproex in the treatment of bipolar disorder in youths.

Original languageEnglish (US)
Pages (from-to)1224-1230
Number of pages7
JournalJournal of the American Academy of Child and Adolescent Psychiatry
Volume41
Issue number10
DOIs
StatePublished - Oct 2002

Fingerprint

Valproic Acid
Bipolar Disorder
Brief Psychiatric Rating Scale
Safety
Nausea
Vomiting
Headache
Diarrhea
Placebos
Demography
Depression
Therapeutics

Keywords

  • Adolescents
  • Bipolar disorder
  • Children
  • Divalproex

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Developmental and Educational Psychology

Cite this

Wagner, K. D., Weller, E. B., Carlson, G. A., Sachs, G., Biederman, J., Frazier, J. A., ... Bowden, C. (2002). An Open-Label Trial of Divalproex in Children and Adolescents with Bipolar Disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 41(10), 1224-1230. https://doi.org/10.1097/00004583-200210000-00012

An Open-Label Trial of Divalproex in Children and Adolescents with Bipolar Disorder. / Wagner, Karen Dineen; Weller, Elizabeth B.; Carlson, Gabrielle A.; Sachs, Gary; Biederman, Joseph; Frazier, Jean A.; Wozniak, Patricia; Tracy, Katherine; Weller, Ronald A.; Bowden, Charles.

In: Journal of the American Academy of Child and Adolescent Psychiatry, Vol. 41, No. 10, 10.2002, p. 1224-1230.

Research output: Contribution to journalArticle

Wagner, KD, Weller, EB, Carlson, GA, Sachs, G, Biederman, J, Frazier, JA, Wozniak, P, Tracy, K, Weller, RA & Bowden, C 2002, 'An Open-Label Trial of Divalproex in Children and Adolescents with Bipolar Disorder', Journal of the American Academy of Child and Adolescent Psychiatry, vol. 41, no. 10, pp. 1224-1230. https://doi.org/10.1097/00004583-200210000-00012
Wagner, Karen Dineen ; Weller, Elizabeth B. ; Carlson, Gabrielle A. ; Sachs, Gary ; Biederman, Joseph ; Frazier, Jean A. ; Wozniak, Patricia ; Tracy, Katherine ; Weller, Ronald A. ; Bowden, Charles. / An Open-Label Trial of Divalproex in Children and Adolescents with Bipolar Disorder. In: Journal of the American Academy of Child and Adolescent Psychiatry. 2002 ; Vol. 41, No. 10. pp. 1224-1230.
@article{5c338d1a027248fd86978193aa8af770,
title = "An Open-Label Trial of Divalproex in Children and Adolescents with Bipolar Disorder",
abstract = "Objective: This study evaluated the safety and effectiveness of divalproex sodium (Depakote{\circledR}) in the treatment of youths with bipolar disorder. Method: Forty bipolar disorder patients aged 7 to 19 years, with a manic, hypomanic, or mixed episode, enrolled in an open-label study of divalproex (2-8 weeks), followed by a double-blind, placebo-controlled period (8 weeks). Results: Twenty-two subjects (61{\%}) showed ≥50{\%} improvement in Mania Rating Scale (MRS) scores during the open-label period. Significant (p < .001) improvements from baseline were seen for mean scores of all efficacy measures, including the MRS, Manic Syndrome Scale, Behavior and Ideation Scale, Brief Psychiatric Rating Scale, Clinical Global Impressions Severity scale, and Hamilton Rating Scale for Depression. Of the 23 subjects who discontinued the study during the open-label period, 6 (15{\%}) discontinued for ineffectiveness, 6 (15{\%}) for intolerance, 6 (15{\%}) for noncompliance, and 6 (15{\%}) for other reasons. Adverse events were generally mild or moderate in severity, with the most common being headache, nausea, vomiting, diarrhea, and somnolence. Laboratory data results were unremarkable. Too few subjects participated in the double-blind period for statistical analysis. Conclusion: This study provides preliminary support for the safety and effectiveness of divalproex in the treatment of bipolar disorder in youths.",
keywords = "Adolescents, Bipolar disorder, Children, Divalproex",
author = "Wagner, {Karen Dineen} and Weller, {Elizabeth B.} and Carlson, {Gabrielle A.} and Gary Sachs and Joseph Biederman and Frazier, {Jean A.} and Patricia Wozniak and Katherine Tracy and Weller, {Ronald A.} and Charles Bowden",
year = "2002",
month = "10",
doi = "10.1097/00004583-200210000-00012",
language = "English (US)",
volume = "41",
pages = "1224--1230",
journal = "Journal of the American Academy of Child and Adolescent Psychiatry",
issn = "0890-8567",
publisher = "Elsevier Limited",
number = "10",

}

TY - JOUR

T1 - An Open-Label Trial of Divalproex in Children and Adolescents with Bipolar Disorder

AU - Wagner, Karen Dineen

AU - Weller, Elizabeth B.

AU - Carlson, Gabrielle A.

AU - Sachs, Gary

AU - Biederman, Joseph

AU - Frazier, Jean A.

AU - Wozniak, Patricia

AU - Tracy, Katherine

AU - Weller, Ronald A.

AU - Bowden, Charles

PY - 2002/10

Y1 - 2002/10

N2 - Objective: This study evaluated the safety and effectiveness of divalproex sodium (Depakote®) in the treatment of youths with bipolar disorder. Method: Forty bipolar disorder patients aged 7 to 19 years, with a manic, hypomanic, or mixed episode, enrolled in an open-label study of divalproex (2-8 weeks), followed by a double-blind, placebo-controlled period (8 weeks). Results: Twenty-two subjects (61%) showed ≥50% improvement in Mania Rating Scale (MRS) scores during the open-label period. Significant (p < .001) improvements from baseline were seen for mean scores of all efficacy measures, including the MRS, Manic Syndrome Scale, Behavior and Ideation Scale, Brief Psychiatric Rating Scale, Clinical Global Impressions Severity scale, and Hamilton Rating Scale for Depression. Of the 23 subjects who discontinued the study during the open-label period, 6 (15%) discontinued for ineffectiveness, 6 (15%) for intolerance, 6 (15%) for noncompliance, and 6 (15%) for other reasons. Adverse events were generally mild or moderate in severity, with the most common being headache, nausea, vomiting, diarrhea, and somnolence. Laboratory data results were unremarkable. Too few subjects participated in the double-blind period for statistical analysis. Conclusion: This study provides preliminary support for the safety and effectiveness of divalproex in the treatment of bipolar disorder in youths.

AB - Objective: This study evaluated the safety and effectiveness of divalproex sodium (Depakote®) in the treatment of youths with bipolar disorder. Method: Forty bipolar disorder patients aged 7 to 19 years, with a manic, hypomanic, or mixed episode, enrolled in an open-label study of divalproex (2-8 weeks), followed by a double-blind, placebo-controlled period (8 weeks). Results: Twenty-two subjects (61%) showed ≥50% improvement in Mania Rating Scale (MRS) scores during the open-label period. Significant (p < .001) improvements from baseline were seen for mean scores of all efficacy measures, including the MRS, Manic Syndrome Scale, Behavior and Ideation Scale, Brief Psychiatric Rating Scale, Clinical Global Impressions Severity scale, and Hamilton Rating Scale for Depression. Of the 23 subjects who discontinued the study during the open-label period, 6 (15%) discontinued for ineffectiveness, 6 (15%) for intolerance, 6 (15%) for noncompliance, and 6 (15%) for other reasons. Adverse events were generally mild or moderate in severity, with the most common being headache, nausea, vomiting, diarrhea, and somnolence. Laboratory data results were unremarkable. Too few subjects participated in the double-blind period for statistical analysis. Conclusion: This study provides preliminary support for the safety and effectiveness of divalproex in the treatment of bipolar disorder in youths.

KW - Adolescents

KW - Bipolar disorder

KW - Children

KW - Divalproex

UR - http://www.scopus.com/inward/record.url?scp=0036783376&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036783376&partnerID=8YFLogxK

U2 - 10.1097/00004583-200210000-00012

DO - 10.1097/00004583-200210000-00012

M3 - Article

VL - 41

SP - 1224

EP - 1230

JO - Journal of the American Academy of Child and Adolescent Psychiatry

JF - Journal of the American Academy of Child and Adolescent Psychiatry

SN - 0890-8567

IS - 10

ER -